Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration

Cell Proliferation

Volumn 46, Issue 5, 2013, Pages 538-553

  Ayoub, N M ^a   Akl, M R ^a   Sylvester, P W ^a  

^a UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYTOKERATIN 18; CYTOKERATIN 8; GAMMA TOCOTRIENOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; STAT1 PROTEIN; UVOMORULIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG POTENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; BETA CATENIN; CADHERINS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CHROMANS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; INDOLES; KERATIN-18; KERATIN-8; KI-67 ANTIGEN; MCF-7 CELLS; MICE; MICE, INBRED BALB C; NF-KAPPA B; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; STAT1 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; SULFONAMIDES; VIMENTIN; VITAMIN E;

EID: 84884701675     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12059     Document Type: Article

References (61)

1. Gastaldi S, Comoglio PM, Trusolino L (2010) The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res. 12, 208.
2. Andrechek ER, Muller WJ (2000) Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res. 2, 211-216.
3. Hynes NE (2000) Tyrosine kinase signalling in breast cancer. Breast Cancer Res. 2, 154-157.
4. Geho DH, Bandle RW, Clair T, Liotta LA (2005) Physiological mechanisms of tumor-cell invasion and migration. Physiology (Bethesda) 20, 194-200.
5. Porter AC, Vaillancourt RR (1998) Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17, 1343-1352.
6. Elliott BE, Hung WL, Boag AH, Tuck AB (2002) The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can. J. Physiol. Pharmacol. 80, 91-102.
7. Ma PC, Maulik G, Christensen J, Salgia R (2003) c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 22, 309-325.
8. Sattler M, Salgia R (2007) c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr. Oncol. Rep. 9, 102-108.
9. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 15, 2207-2214.
10. Gentile A, Trusolino L, Comoglio PM (2008) The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 27, 85-94.
11. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B et al. (2004) The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23, 5387-5393.
12. Kim YM, Park SY, Pyo H (2009) Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells. Mol. Cancer Res. 7, 1367-1377.
13. Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y et al. (2012) Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21, 66-81.
14. Tomaskovic-Crook E, Thompson EW, Thiery JP (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 11, 213.
15. Dussault I, Bellon SF (2009) From concept to reality: the long road to c-MET and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med. Chem. 9, 221-229.
16. Sylvester PW, Kaddoumi A, Nazzal S, El Sayed KA (2010) The value of tocotrienols in the prevention and treatment of cancer. J. Am. Coll. Nutr. 29, 324S-333S.
17. Wada S, Satomi Y, Murakoshi M, Noguchi N, Yoshikawa T, Nishino H (2005) Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Lett. 229, 181-191.
18. Sylvester PW, Theriault A (2003) Role of tocotrienols in the prevention of cardiovascular disease and breast cancer. Curr. Top. Nutraceutical Res. 1, 121-136.
19. Sylvester PW (2009) Antiproliferative and apoptotic effects of tocotrienols on normal and neoplastic mammary epithelial cells. In: Watson RR, Preedy VR, eds. Tocotrienols: Vitamin E Beyond Tocopherols, pp. 119-140. Boca Raton, FL: CRC Press.
20. Samant GV, Sylvester PW (2006) Gamma-tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif. 39, 563-574.
21. Bachawal SV, Wali VB, Sylvester PW (2010) Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses STAT and Akt signaling in murine mammary tumor cells. Anticancer Res. 30, 429-437.
22. Bachawal SV, Wali VB, Sylvester PW (2010) Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 10, 84.
23. Shah SJ, Sylvester PW (2005) Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity. Exp. Biol. Med. 230, 235-241.
24. Ayoub NM, Bachawal SV, Sylvester PW (2011) Gamma-tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells. Cell Prolif. 44, 516-526.
25. Anderson LW, Danielson KG, Hosick HL (1979) New cell line. Epithelial cell line and subline established from premalignant mouse mammary tissue. In Vitro 15, 841-843.
26. Danielson KG, Anderson LW, Hosick HL (1980) Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Res. 40, 1812-1819.
27. McIntyre BS, Briski KP, Gapor A, Sylvester PW (2000) Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc. Soc. Exp. Biol. Med. 224, 292-301.
28. Shah S, Gapor A, Sylvester PW (2003) Role of caspase-8 activation in mediating vitamin e-induced apoptosis in murine mammary cancer cells. Nutr. Cancer 45, 236-246.
29. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76, 4350-4354.
30. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446.
31. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681.
32. Tallarida RJ (2001) Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther. 298, 865-872.
33. Tallarida RJ (2006) An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 319, 1-7.
34. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. 23, 7212-7220.
35. Lawrence RE, Salgia R (2009) Met molecular mechanisms and therapies in lung cancer. Cell Adh. Migr. 4, 146-152.
36. Yu SG, Thomas AM, Gapor A, Tan B, Qureshi N, Qureshi AA (2006) Dose-response impact of various tocotrienols on serum lipid parameters in 5-week-old female chickens. Lipids 41, 453-461.
37. Yap SP, Yuen KH, Wong JW (2001) Pharmacokinetics and bioavailability of alpha-, gamma-, and delta-tocotrienols under different food status. J. Pharm. Pharmacol. 56, 67-71.
38. Wang Y, Ai J, Chen Y, Wang L, Liu G, Geng M et al. (2011) Synthesis and c-Met kinase inhibition of 3, 5-disubstituted and 3, 5, 7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent. J. Med. Chem. 54, 2127-2142.
39. Micalizzi DS, Farabaugh SM, Ford HL (2010) Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J. Mammary Gland Biol. Neoplasia. 15, 117-134.
40. Takebe N, Warren RQ, Ivy SP (2011) Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res. 13, 211.
41. Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H et al. (2011) Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol. Cancer Ther. 10, 169-177.
42. Reshetnikova G, Troyanovsky S, Rimm DL (2007) Definition of a direct extracellular interaction between met and E-cadherin. Cell Biol. Int. 31, 366-373.
43. Hu J, Shao S, Song Y, Zhao J, Dong Y, Gong L et al. (2010) Hepatocyte growth factor induces invasion and migration of ovarian cancer cells by decreasing the expression of E-cadherin, beta-catenin, and caveolin-1. Anat. Rec. (Hoboken) 293, 1134-1139.
44. Tomooka Y, Imagawa W, Nandi S, Bern HA (1983) Growth effect of lithium on mouse mammary epithelial cells in serum- free collagen gel culture. J. Cell. Physiol. 117, 290-296.
45. Anderson LW, Danielson KG, Hosick HL (1981) Metastatic potential of hyperplastic alveolar nodule derived mouse mammary tumor cells following intravenous inoculation. Eur. J. Cancer Clin. Oncol. 17, 1001-1008.
46. Brooks SC, Locke ER, Soule HD (1973) Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J. Biol. Chem. 248, 6251-6253.
47. Nohara K, Wang F, Spiegel S (1998) Glycosphingolipid composition of MDA-MB-231 and MCF-7 human breast cancer cell lines. Breast Cancer Res. Treat. 48, 149-157.
48. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P (1993) Proliferation index as a prognostic marker in breast cancer. Cancer 71, 3926-3931.
49. Sahin AA, Ro J, Ro JY, Blick MB, el-Naggar AK, Ordonez NG et al. (1991) Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68, 549-557.
50. Esteva FJ, Hortobagyi GN (2004) Prognostic molecular markers in early breast cancer. Breast Cancer Res. 6, 109-118.
51. Murai M, Shen X, Huang L, Carpenter WM, Lin CS, Silverman S et al. (2004) Overexpression of c-Met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion. Int. J. Oncol. 25, 831-840.
52. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M (2001) Downregulation of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 20, 8125-8135.
53. Xie LQ, Bian LJ, Li Z, Li Y, Li ZX, Li B (2010) Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann. Surg. Oncol. 17, 1927-1936.
54. Koefinger P, Wels C, Joshi S, Damm S, Steinbauer E, Beham-Schmid C et al. (2011) The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators. Pigment Cell Melanoma Res. 24, 382-385.
55. Kim CH, Kim J, Kahng H, Choi EC (2007) Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma. Ann. Surg. Oncol. 14, 1565-1574.
56. Han SU, Lee HY, Lee JH, Kim WH, Nam H, Kim H et al. (2005) Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann. Surg. 242, 676-683.
57. Cimpean AM, Suciu C, Ceausu R, Tatucu D, Muresan AM, Raica M (2008) Relevance of the immunohistochemical expression of cytokeratin 8/18 for the diagnosis and classification of breast cancer. Rom. J. Morphol. Embryol. 49, 479-483.
58. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253-1270.
59. Mulligan AM, Pinnaduwage D, Bane AL, Bull SB, O'Malley FP, Andrulis IL (2011) CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the ontario site of the breast cancer family registry. Cancer 117, 1350-1359.
60. Zucchi I, Sanzone S, Astigiano S, Pelucchi P, Scotti M, Valsecchi V et al. (2007) The properties of a mammary gland cancer stem cell. Proc. Natl. Acad. Sci. USA 104, 10476-10481.
61. Suzuki R, Atherton AJ, O'Hare MJ, Entwistle A, Lakhani SR, Clarke C (2000) Proliferation and differentiation in the human breast during pregnancy. Differentiation 66, 106-115.